8-K: Bausch + Lomb Reports Strong Q2 Growth, Raises Guidance

Bausch + Lomb Corporation announced robust second-quarter 2026 results, with revenue up 9% and full-year guidance increased.

Summary

• Bausch + Lomb Corporation reported second-quarter 2026 revenue of $1.394 billion, a 9% increase year-over-year.
• The company experienced broad-based growth across all segments, with double-digit revenue growth in Surgical and Pharmaceuticals.
• Adjusted EBITDA (non-GAAP) was $241 million, and the company raised its full-year 2026 revenue and Adjusted EBITDA guidance.
• Net loss attributable to Bausch + Lomb Corporation improved to $14 million from $62 million in the prior year's second quarter.
• Cash flow from operations significantly increased to $153 million from $35 million in the same period last year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, improved profitability, and raised forward-looking guidance, indicating robust operational performance and positive market reception.

Positives

• Revenue increased by 9% to $1.394 billion in Q2 2026 compared to Q2 2025.
• Constant currency revenue growth was 8% year-over-year.
• Surgical segment revenue grew 19% (16% constant currency), driven by premium IOLs.
• Pharmaceuticals segment revenue grew 15% (14% constant currency), driven by MIEBO and XIIDRA.
• Operating income turned positive at $83 million, a significant improvement from an $11 million loss in Q2 2025.
• Net loss narrowed to $14 million from $62 million in Q2 2025.
• Adjusted EBITDA (non-GAAP) increased by $50 million to $241 million.
• Cash flow from operations increased by $118 million to $153 million.

Negatives

• The company reported a GAAP Net Loss of $14 million for the second quarter of 2026.
• Amortization of intangible assets was $57 million in Q2 2026.
• Restructuring, integration, and transformation costs were $11 million in Q2 2026.

Risks

• The enVista Beyond investigational IOL narrowly missed predefined performance targets related to depth of focus and intermediate visual performance, though it met co-primary effectiveness endpoints.
• Forward-looking statements are subject to risks and uncertainties, including those discussed in SEC filings, potential separation of Bausch + Lomb, market conditions, regulatory approvals, and economic factors.
• The company's guidance does not take into consideration any changes in tariff policy, given the dynamic nature of the situation.
• Risks related to the adoption and integration of artificial intelligence solutions into business operations are mentioned.

Future Outlook

Full-year 2026 revenue guidance was raised to $5.440 billion $5.540 billion (5.8% 7.7% constant currency growth), and full-year Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) guidance was raised to $1.025 billion $1.075 billion.

Management Comments

• "Broad-based growth across all segments, with double digit revenue growth from Surgical and Pharmaceuticals."
• "These have been themes since we unveiled our three-year plan for growth at Investor Day last November, and in the second quarter progress continued at an accelerated pace."
• "Launch momentum continues, with Blink Triple Care Preservative Free contributing to +12% reported revenue growth for the Blink franchise; recent pipeline milestones include topline results from a pivotal clinical study evaluating the enVista Beyond investigational IOL."

Industry Context

StockSavvy.ai notes that Bausch + Lomb's reported strong Q2 growth and raised guidance align with a positive trend in the eye health sector, driven by innovation in areas like premium IOLs and pharmaceutical treatments for dry eye.

Comparison to Industry Standards

• The 19% reported revenue growth in the Surgical segment, with premium IOLs now at 13% of total Surgical revenue (up from 6% in 2025), indicates strong performance in a competitive market for ophthalmic devices.
• Combined revenue growth of 27% for MIEBO and XIIDRA in the first half of 2026 suggests successful market penetration and demand for these pharmaceutical products, potentially outperforming broader pharmaceutical segment growth rates.
• The daily SiHy portfolio and Biotrue ONEday/ULTRA monthly contact lenses show balanced global performance, reflecting continued demand for advanced contact lens materials and convenient wear options in the contact lens market.

Stakeholder Impact

• Shareholders are likely to view the increased revenue, improved profitability, and raised guidance positively, potentially leading to increased stock value.
• Employees may see continued job security and potential for bonuses tied to performance metrics like Adjusted EBITDA.
• Customers in the pharmaceutical segment benefit from continued growth and availability of products like MIEBO and XIIDRA.
• Suppliers may experience increased demand for materials and services due to the company's revenue growth.

Next Steps

• Bausch + Lomb is conducting a comprehensive review of the enVista Beyond IOL study data.
• The company will engage with regulatory authorities on next steps to support submission of the enVista Beyond IOL program.
• The company will continue to execute its three-year plan for growth.

Key Dates

Recommendation

The company demonstrated strong Q2 performance with broad-based revenue growth, significant improvements in profitability and cash flow, and raised full-year guidance. This indicates robust execution and positive market dynamics, warranting a strong buy recommendation.

Keywords

Bausch + Lomb, Eye Health, Contact Lenses, Surgical, Pharmaceuticals, Intraocular Lenses, Financial Results, Guidance